Skip Navigation



NDT Advance Access published online on January 3, 2008

Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfm785
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
23/4/1241    most recent
gfm785v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kimmel, M.
Right arrow Articles by Alscher, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kimmel, M.
Right arrow Articles by Alscher, D. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org



Improved Estimation of Glomerular Filtration Rate by Serum Cystatin C in Preventing Contrast Induced Nephropathy by N-Acetylcysteine or Zinc-Preliminary Results

Martin Kimmel1, Moritz Butscheid2, Stefanie Brenner2, Ulrich Kuhlmann1, Ulrich Klotz2 and Dominik Mark Alscher1

1 Department of General Internal Medicine and Nephrology, Robert Bosch Hospital Germany 2 Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany

Correspondence and offprint requests to: Martin Kimmel, Robert Bosch Hospital, Auerbachstr, 110, D-70376, Stuttgart, Germany. Tel: +49-711-8101-5722; Fax: +49-711-8101-3792; E-mail: vm.kimmel{at}t-online.de



  Abstract

Background. Prevention of contrast media (CM) induced nephropathy (CIN) by prophylaxis (e.g. N-acetylcysteine; NAC) is controversially discussed. Up to now, assessment of kidney function has been based on measurements of serum creatinine, although this biomarker has several limitations. We investigated NAC and zinc (Zn) for the prevention of CIN by monitoring creatinine and cystatin C.

Methods. In a prospective, placebo-controlled, double blind trial, patients with moderately impaired kidney function receiving low-osmolar, non-ionic CM were randomly assigned to an oral treatment for 2 days with 1.2 g/day of NAC (n = 19), for 1 day with 60 mg/day of Zn (n = 18) or placebo (n = 17). All patients received peri-procedurally 1 ml/kg/h of 0.45% saline for 24 h. At baseline, prior to exposure of CM, 2 and 6 days after CM, creatinine and cystatin C were measured.

Results. There was no difference in the incidence of CIN, but a significant drop in creatinine (P < 0.05) was observed in all patients during volume expansion. Creatinine showed no increase after CM and it was normalized to the baseline values in all groups at the study end. In contrast, 2 days after CM there was a significant rise in cystatin C in the Zn (P = 0.012) and the placebo (P = 0.041) group, whereas NAC prevented this deterioration of kidney function.

Conclusions. Cystatin C seems to reflect CM-induced changes in kidney function better than creatinine. NAC and Zn have no effect in preventing CIN by the standard definition, but based on cystatin C we can confirm a preventive effect of NAC. It appears mandatory to assess kidney function by cystatin C in CIN intervention trials, because relying on creatinine can be misleading.

Keywords: contrast-induced nephropathy; cystatin C; NAC; volume expansion; zinc

Received for publication: 20. 6.07
Accepted in revised form: 8.10.07


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
S.-H. Jo, B.-K. Koo, T.-J. Youn, and H.-S. Kim
Conclusion of recent 'osmolality trials' in preventing contrast-induced nephropathy by NAC--what is the standard?
Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2424 - 2424.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Kimmel and D. M. Alscher
Reply
Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2424 - 2425.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.